LXRX — Lexicon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $406.29m
- $335.77m
- $1.20m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 322 | 24 | 0.298 | 0.139 | 1.2 |
Cost of Revenue | |||||
Gross Profit | 319 | 22.1 | 0.298 | 0.139 | 1.12 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 181 | 70.8 | 87.4 | 101 | 173 |
Operating Profit | 141 | -46.8 | -87.1 | -101 | -172 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 124 | -58.6 | -87.8 | -102 | -177 |
Provision for Income Taxes | |||||
Net Income After Taxes | 130 | -58.6 | -87.8 | -102 | -177 |
Net Income Before Extraordinary Items | |||||
Net Income | 130 | -58.6 | -87.8 | -102 | -177 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 130 | -58.6 | -87.8 | -102 | -177 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.27 | -1.72 | -0.603 | -0.615 | -0.801 |